author-photo

Li Shen

Peking University

84

Papers

1464

Citations

Citation Trend

Filter By

Papers (61) Sort By

Journal Conference Others

P-144 A comparative analysis of secondary data from the ToGA and EVIDENCE studies on the effectiveness of trastuzumab plus chemotherapy in Asian patients with HER2+ metastatic gastric cancer

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
LBA-4 Initial data from the phase 3 KEYNOTE-811 study of trastuzumab and chemotherapy with or without pembrolizumab for HER2-positive metastatic gastric or gastroesophageal junction (G/GEJ) cancer

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
O-15 Randomized, phase 3 study of second-line tislelizumab vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma (RATIONALE 302) in the overall population and Europe/North America subgroup

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (1)
P-138 Margetuximab combined with anti-PD-1 (retifanlimab) or anti-PD-1/LAG-3 (tebotelimab) +/- chemotherapy in first-line therapy of advanced/metastatic HER2+ gastroesophageal junction or gastric cancer

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Programmable Synthetic Protein Circuits for the Identification and Suppression of Hepatocellular Carcinoma

2020 Molecular Therapy - Oncolytics
Show All
- Source
- Cite
- Save
Citations (4)
P-34 The randomized, double-blind, placebo-controlled phase 3 trial KEYNOTE-975: Pembrolizumab vs placebo in patients with esophageal carcinoma receiving concurrent definitive chemoradiotherapy

2020 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network

2020 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (26)
PES1 is regulated by CD44 in liver cancer stem cells via miR‐105‐5p

2019 FEBS Letters
Show All
- Source
- Cite
- Save
Citations (5)
Prognostic implications of epidermal growth factor receptor variant III expression and nuclear translocation in Chinese human gliomas

2019 Chinese Journal of Cancer Research
Show All
- Source
- Cite
- Save
Citations (7)
840TiPA phase Ib/II study of AK104, a PD-1/CTLA-4 bispecific antibody, combined with mXELOX as first-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma

2019 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (1)